CIBC Private Wealth Group LLC Has $1.52 Million Stock Position in Charles River Laboratories International, Inc. $CRL

CIBC Private Wealth Group LLC reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 34.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,728 shares of the medical research company’s stock after selling 5,141 shares during the quarter. CIBC Private Wealth Group LLC’s holdings in Charles River Laboratories International were worth $1,522,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Jones Financial Companies Lllp boosted its stake in shares of Charles River Laboratories International by 167.6% in the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock valued at $253,000 after purchasing an additional 1,074 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Charles River Laboratories International during the first quarter worth approximately $418,000. Allworth Financial LP lifted its holdings in Charles River Laboratories International by 172.7% in the second quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock valued at $45,000 after buying an additional 190 shares during the period. Creative Planning lifted its holdings in Charles River Laboratories International by 7.1% in the second quarter. Creative Planning now owns 8,894 shares of the medical research company’s stock valued at $1,349,000 after buying an additional 586 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Charles River Laboratories International by 57.4% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 17,977 shares of the medical research company’s stock valued at $2,728,000 after acquiring an additional 6,558 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CRL. Morgan Stanley set a $185.00 target price on shares of Charles River Laboratories International in a research report on Monday, December 1st. JPMorgan Chase & Co. raised their price target on Charles River Laboratories International from $165.00 to $190.00 and gave the stock a “neutral” rating in a research report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, TD Cowen cut their target price on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, February 20th. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $206.15.

Charles River Laboratories International Trading Up 0.3%

CRL opened at $153.52 on Monday. The firm’s fifty day moving average is $185.42 and its two-hundred day moving average is $180.83. The firm has a market cap of $7.56 billion, a PE ratio of -51.86, a price-to-earnings-growth ratio of 2.63 and a beta of 1.64. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $228.88. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.33 by $0.06. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company had revenue of $994.23 million during the quarter, compared to analyst estimates of $986.98 million. During the same quarter in the previous year, the business earned $2.66 EPS. The firm’s revenue was down .8% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.